Clinical Trial Update: Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ranibizumab for choroidal neovascularization in patients with pseudoxanthoma elasticum has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Pseudoxanthoma Elasticum

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University Hospital, Bonn | Conditions: Choroidal Neovascularization | Phase 2 | Status: COMPLETED